Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) During the 2023–2024 Respiratory Virus Season [October 23, 2023, 3:30 PM ET]

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.). Health Alert Network (HAN)
• Description:
  October 23, 2023, 3:30 PM ET
  
  CDCHAN-00499
  
  The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to provide options for clinicians to protect infants from respiratory syncytial virus (RSV) in the context of a limited supply of nirsevimab, a long-acting monoclonal antibody immunization product recommended for preventing RSV-associated lower respiratory tract disease in infants.
  
  In the context of limited supply during the 2023–2024 RSV season, CDC recommends prioritizing available nirsevimab 100mg doses for infants at the highest risk for severe RSV disease: young infants (age <6 months) and infants with underlying conditions that place them at highest risk for severe RSV disease. Recommendations for using 50mg doses remain unchanged at this time. Avoid using two 50mg doses for infants weighing ≥5 kilograms (≥11 pounds) to preserve supply of 50mg doses for infants weighing <5 kilograms (<11 pounds). Providers should be aware that some insurers may not cover the cost of two 50mg doses for an individual infant.
  
  CDC further recommends that providers suspend using nirsevimab in palivizumab-eligible children aged 8–19 months for the 2023–2024 RSV season. These children should receive palivizumab per American Academy of Pediatrics (AAP) recommendations. Nirsevimab should continue to be offered to American Indian and Alaska Native children aged 8–19 months who are not palivizumab-eligible and who live in remote regions, where transporting children with severe RSV for escalation of medical care is more challenging or in communities with known high rates of RSV among older infants and toddlers. Prenatal care providers should discuss potential nirsevimab supply concerns when counseling pregnant people about RSVpreF vaccine (Abrysvo, Pfizer) as maternal vaccination is effective and will reduce the number of infants requiring nirsevimab during the RSV season.
  
  
• Content Notes:
  Notice of Possible Alert Expiration: The CDC Health Alert, Advisory, Update, and Info Service announcements, distributed by the Health Alert Network (HAN), were active on the date they were originally published. Publication dates have been added to Titles for clarity. A CDC Health Alert, Advisory, Update, and Info Service announcement may expire at any time. They may also be updated or superseded according to later developments. None of the CDC Health Alert, Advisory, Update, or Info Service announcements in the Stacks HAN Collection should be assumed to be current or active. Stacks preserves HAN announcements in order to maintain a record of past CDC actions. Stacks in not designed for up-to-the-minute notifications. For the list of current CDC Health Alert, Advisory, Update, or Info Service announcements, patrons should visit the Health Alert Network (HAN) webpage at https://www.cdc.gov/han/php/about/index.html. For up to the minute reports, subscribe to the HAN email alert system hosted by CDC News & Updates at https://tools.cdc.gov/campaignproxyservice/subscriptions.aspx?topic_id=USCDC_486
  
  Categories of Health Alert Network (HAN) messages:
  
  Health Alert: Requires immediate action or attention, highest level of importance.
  
  Health Advisory: May not require immediate action; provides important information for a specific incident or situation.
  
  Health Update: Unlikely to require immediate action; provides updated information regarding an incident or situation.
  
  HAN Info Service: Does not require immediate action; provides general public health information.
  
  
• Subjects:
  Antibodies, Monoclonal, Humanized/supply & Distribution Antiviral Agents/supply & Distribution Infant Respiratory Syncytial Virus Infections/prevention & Control
• Keywords:
  HAN Health Alert Network
• Source:
  HAN ; 499
• Series:
  Health Alert Network
• Subseries:
  CDC Health Advisory
• Publisher:
  Centers for Disease Control and Prevention (CDC) (U.S.)
• Document Type:
  Text
• Genre:
  Alert
• Place as Subject:
  United States
• Rights:
  Public Domain
• Pages in Document:
  4 unnumbered pages
• Issue:
  00499
• Collection(s):
  Health Alert Network (HAN)
• Main Document Checksum:
  urn:sha-512:67132e15ceaf10e4667ebaed4d1a6ed7ade17783ace0be6aa5e7f05379323e3706a65ca54bf693c92977069afee8d6e2928d2500c03dcf52a69b4b3ff8dfa750
• Download URL:
  https://stacks.cdc.gov/view/cdc/134514/cdc_134514_DS1.pdf
• File Type:
  [PDF - 174.47 KB ]